Photo Credit: FatCamera
The following is a summary of “Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18),” published in the November 2024 issue of Oncology by Fagotti et al.
Patients with platinum-sensitive recurrent ovarian cancer (PSROC) peritoneal recurrence often undergo secondary cytoreductive surgery (SCS), but the role of hyperthermic intraperitoneal chemotherapy (HIPEC) remains uncertain.
Researchers conducted a prospective study to evaluate whether HIPEC improves progression-free survival (PFS) in patients with PSROC.
They randomly assigned 167 patients to undergo either SCS alone (n=85) or SCS plus HIPEC (n=82) with cisplatin (CDDP) 75 mg/m at 41.5° C for 60 minutes. Both groups received postoperative platinum-based chemotherapy. The primary endpoint was PFS, and the secondary endpoints included post-recurrence survival (PRS) and safety.
The results showed that the median PFS was 23 months (95% CI, 17 to 29) for the SCS group and 25 months (95% CI, 18 to 32) for the SCS plus HIPEC group. The probability of PRS at 5 years was 61.6% (95% CI, 50.8 to 72.4) in the SCS group and 75.9% (95% CI, 66.5 to 85.3) in the SCS plus HIPEC group. The incidence of postoperative AEs of any grade was similar between both groups.
They concluded that adding HIPEC to SCS did not improve PFS for patients with PSROC.
Source: ascopubs.org/doi/10.1200/JCO.24.00686
